Skip to main content
. 2020 May 30;20(2):1033–1054. doi: 10.3892/ol.2020.11690

Figure 3.

Figure 3.

Immunohistochemical survivin expression in different clinical stages of endometrial carcinoma; (A) 30% of immunopositive cells in clinical stage I; (B) 40% of immunopositive cells in clinical stage I; (C) 60% of immunopositive cells in clinical stage II; (D) 70% of immunopositive cells in clinical stage III. Original magnification, ×100.